Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and
Resignation of William M. Wells as Chairman

    



    
</pre>
<p>MISSISSAUGA, Ontario, <span class="xn-chron">Dec. 13, 2010</span> /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that Robert A. Ingram, Valeant's lead independent director, was appointed as Chairman of the Board of Directors, replacing William M. Wells, who has resigned from the Board to pursue other interests.</p>
<pre>
    

    About Valeant
    
</pre>
<p>Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant can be found at <a href="http://www.valeant.com">www.valeant.com</a>.</p>
<pre>
    

    (Logo: <a href="http://photos.prnewswire.com/prnh/20101025/LA87217LOGO">http://photos.prnewswire.com/prnh/20101025/LA87217LOGO</a>)

    
</pre>
<p> </p>
<p> </p>
<pre>
    
    Contact Information:
    Laurie W. Little
    949-461-6002
    [email protected]






    

For further information: Laurie W. Little of Valeant Pharmaceuticals International, Inc., [phone], [email protected] Web Site: http://www.valeant.com